Psilocybin, LSD and MDMA in Canada: What Is Legal in Each Province? — 2026 Guide

Last reviewed: August 14, 2026. This article is for education and public information and is not legal advice. Canadian drug law can change, and federal regulatory changes are scheduled for October 1, 2026, so current official sources should always be checked before relying on this information.

Interest in psychedelic-assisted mental health care has grown quickly in Canada. At the same time, public discussion can create confusion because three very different ideas are often mixed together: legalization, decriminalization, and authorized medical or scientific access. They are not the same thing.

The most important point is that psilocybin, LSD and MDMA are primarily controlled by federal law. Provincial governments can regulate health professionals, clinics and treatment services, but a province cannot simply make a federally controlled substance legal for the general public. Legal possession, sale, production or administration normally requires an authorization recognized under federal law.

The Federal Baseline Across Canada

Canada’s Controlled Drugs and Substances Act (CDSA) is the central federal law governing these substances. It applies across every province and territory.

Psilocybin and “magic mushrooms”

Health Canada states that the production, sale and possession of magic mushrooms, psilocybin and psilocin are illegal unless the activity is specifically authorized, for example through a licence, exemption or applicable regulation. The fact that mushroom dispensaries may operate openly in some Canadian cities does not make those sales legal under federal law.

Health Canada also states that there is currently no approved therapeutic product containing psilocybin in Canada. Research is ongoing, and some patients may be able to access psilocybin legally through authorized clinical trials, the Special Access Program, or an individual subsection 56(1) exemption where the legal requirements are met.

LSD

LSD is controlled under Schedule III of the CDSA. Health Canada states that activities such as possession, sale and production are illegal unless authorized for medical, scientific or industrial purposes. Research involving LSD therefore requires the appropriate federal authorization; ordinary personal possession is not made legal because a person intends to use it for self-exploration or mental health.

MDMA

MDMA is controlled under Schedule I of the CDSA. Possession, sale and production are illegal unless authorized for medical, scientific or industrial purposes. Health Canada notes that MDMA is being studied for possible therapeutic applications, including post-traumatic stress disorder and anxiety, but there is currently no approved therapeutic product containing MDMA in Canada.

For certain serious or life-threatening conditions, regulated practitioners may request access to non-marketed drugs through Health Canada’s Special Access Program. Health Canada has also created specific exemptions that permit authorized activities with psilocybin and MDMA when a Special Access Program authorization or qualifying clinical trial is in place. These are controlled legal pathways, not general permission for personal possession or unsupervised treatment.

Province-by-Province: What Actually Changes?

British Columbia

British Columbia is the province most often associated with drug decriminalization, but the details matter. A federal exemption allowed adults in B.C. to possess small cumulative amounts of certain illegal drugs for personal use beginning January 31, 2023. The substances covered included opioids, cocaine, methamphetamine and MDMA. Psilocybin and LSD were not part of that exemption.

That B.C. exemption expired on January 31, 2026, and the province stated that it would not seek renewal. Therefore, as of August 14, 2026, there is no longer a province-wide B.C. decriminalization exemption for personal possession of MDMA under that pilot. The normal federal CDSA rules again provide the legal baseline.

Alberta

Alberta has taken a different approach. It has a provincial licensing framework specifically for psychedelic drug treatment services. Providers generally must be licensed under Alberta’s Mental Health Services Protection Act and regulation and must follow provincial psychedelic treatment standards. Approved clinical research trials are treated differently under the provincial framework.

This is important, but it does not mean psychedelics are generally legal in Alberta. Alberta’s licence regulates the treatment service. Federal authorization is still required for possession, supply, prescribing, administering or other controlled activities where federal law requires it. A provincial clinic licence does not replace federal drug authorization.

Ontario

Ontario has no general provincial legalization or decriminalization scheme for psilocybin, LSD or MDMA. The federal CDSA remains the baseline. Ontario separately regulates health professions and controlled health acts, including prescribing or dispensing drugs and the regulated practice of psychotherapy. A health professional must therefore consider both federal drug law and the limits of their provincial professional scope.

Quebec

Quebec also remains subject to the federal CDSA for possession, production and sale of psilocybin, LSD and MDMA. I found no current province-wide Quebec exemption that makes personal possession of these three substances generally legal or decriminalized. Quebec continues to regulate its own health professions and health services, but federal authorization remains necessary for controlled-drug activities.

Manitoba and Saskatchewan

In Manitoba and Saskatchewan, the same federal legal baseline applies. I found no current federal exemption creating broad personal-possession decriminalization for psilocybin, LSD or MDMA in either province. Authorized research or medical activity must follow the applicable federal pathway as well as provincial professional and health-service rules.

New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador

The Atlantic provinces are also governed by the federal CDSA with respect to these substances. I found no current broad federal exemption for general personal possession of psilocybin, LSD or MDMA in these provinces. Clinical research and specially authorized medical access remain different from ordinary possession or retail sale.

Yukon, Northwest Territories and Nunavut

The federal CDSA applies in all three territories. I found no current broad exemption making personal possession of psilocybin, LSD or MDMA generally legal there. As elsewhere in Canada, specific medical, scientific or public-interest exemptions can create lawful access for defined people and purposes without legalizing the substance for the general public.

Legalization, Decriminalization and Medical Authorization Are Different

Legalization means the law permits an activity within a regulated framework. Decriminalization usually means specified criminal penalties are removed or not applied in defined circumstances, but the substance may still remain illegal. Medical or scientific authorization is narrower: a specific patient, practitioner, researcher, clinic or licensed dealer may be permitted to conduct activities that would otherwise be prohibited.

This distinction is especially important in psychedelic mental health care. A person having a therapist, counsellor, facilitator or “psychedelic assistant” does not by itself create a legal exemption to possess or obtain psilocybin, LSD or MDMA. The legal status of the substance and the authorization to possess, supply or administer it must be established separately.

What This Means for Mental Health Practice

There is an important difference between providing mental health support and providing a controlled psychedelic drug. A qualified professional may be able to offer psychotherapy, preparation, harm-reduction education or integration support within their lawful professional scope. That professional support does not automatically authorize the possession, sale or administration of a controlled substance.

In legitimate clinical research and authorized treatment pathways, screening, informed consent, product quality, professional oversight, monitoring and follow-up are central parts of the process. This is one reason research findings from controlled clinical settings should not be interpreted as evidence that unsupervised or illegally sourced psychedelic use has the same risk-benefit profile.

A Note About the Coming October 2026 Regulatory Change

Health Canada states that several current controlled-substance class exemptions will be revoked when the new Controlled Substances Regulations take effect on October 1, 2026. This does not mean psychedelics will suddenly become legal for general use. It means the regulatory framework used for some authorized activities is changing. This article should therefore be reviewed again after October 1, 2026.

Conclusion

As of August 14, 2026, psilocybin mushrooms, LSD and MDMA are not generally legal for personal possession, sale or production in Canada. Federal law controls the substances across the country. Provincial differences mainly affect health-service delivery, professional regulation and special treatment frameworks rather than creating general legalization.

British Columbia’s temporary decriminalization pilot has ended. Alberta has a specific licensing system for psychedelic drug treatment services. In Ontario, Quebec and the other provinces and territories, the federal CDSA remains the key legal baseline unless a specific federal authorization, clinical trial, Special Access Program pathway or exemption applies.

For people interested in psychedelics for mental health, the safest legal interpretation is simple: promising research is not the same as general legalization. Professional support, appropriate screening and a lawful access pathway remain essential parts of responsible care.

Official Sources Reviewed

Health Canada — Psilocybin and psilocin (Magic mushrooms); Health Canada — LSD; Health Canada — MDMA; Health Canada — Exemptions from provisions of the Controlled Drugs and Substances Act; Health Canada — Special Access Program; Government of British Columbia — Decriminalizing people who use drugs in B.C.; Government of Alberta — Psychedelic drug treatment service provider licensing. Sources checked August 14, 2026.